Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

19:01
03/19/19
03/19
19:01
03/19/19
19:01

Sage says Zulresso approval represents 'game-changing approach' to PPD

Sage Therapeutics announced today the U.S. Food and Drug Administration has approved ZULPRESSO injection for the treatment of postpartum depression. ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth. ZULRESSO is expected to be available in late June following scheduling by the U.S. Drug Enforcement Administration, which is expected to occur within 90 days. "Today's approval of ZULRESSO represents a game-changing approach to treating PPD," said Samantha Meltzer Brody, M.D., M.P.H., Ray M Hayworth Distinguished Professorship of Mood and Anxiety Disorders and director of the Perinatal Psychiatry Program, UNC Center for Women's Mood Disorders and primary investigator of the ZULRESSO clinical trials. "The potential to rapidly reduce symptoms in this critical disorder is an exciting milestone in women's mental health. PPD is recognized to have a significant and long-term impact on women and their families, but with ZULRESSO we may finally have the opportunity to change that." "We are proud to be a part of this important moment in mental health, creating the opportunity for an unprecedented change in the way postpartum depression is thought about and treated moving forward," said Jeff Jonas, M.D., chief executive officer of Sage. "We are grateful for the patients, researchers, healthcare providers, advocates, caregivers and Sage employees who helped secure the approval of the first medicine specifically for postpartum depression. Not only do we believe ZULRESSO will address an important need for women's mental health, the impact of PPD is multi-generational, and we look forward to bringing ZULRESSO to patients in urgent need of a new treatment option. We believe ZULRESSO will be a catalyst in starting a new dialogue emphasizing the importance of women's mental health, and the importance of diagnosing and treating PPD."

  • 19

    Mar

SAGE Sage Therapeutics
$156.08

-0.89 (-0.57%)

02/22/19
GUGG
02/22/19
INITIATION
Target $205
GUGG
Buy
Sage Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated Sage Therapeutics with a Buy rating and $205 price target, as he believes Zulresso and SAGE-217 have generated impressive data in PPD and MDD. The analysts, who thinks those drugs "have the potential to change the treatment paradigm for treating mood disorders," projects Zulresso and SAGE-217 could generate sales in the $3B-$5B range.
02/19/19
PIPR
02/19/19
NO CHANGE
Target $206
PIPR
Overweight
Piper sees 'significant unrealized value' in shares of Sage Therapeutics
Piper Jaffray analyst Danielle Brill keeps an Overweight rating on Sage Therapeutics with a $206 price target after the company reported fiscal 2018 results and an update on its pipeline. Enrollment in the SAGE-217 pivotal Phase 3 major depressive disorder trial is reportedly going well and top-line data are now expected by Q4 of 2019 or Q1 of 2020, Brill tells investors in a post-earnings research note. The analyst sees "significant unrealized value" for SAGE-217 and expects "various upcoming catalysts" to drive Sage shares higher.
01/07/19
PIPR
01/07/19
NO CHANGE
Target $206
PIPR
Overweight
Sage could be up over 50% folllowing 'clear win' in PPD, says Piper Jaffray
After Sage Therapeutics reported top-line results from the Phase 3 ROBIN study in women with postpartum depression, or PPD, Piper Jaffray analyst Danielle Brill said the data were "impressive and looked clean across the board" in a note titled "Clear Win as SAGE-217 Knocks It Out of the PPD Park." The analyst, who expects over 50% upside for Sage shares today, keeps an Overweight rating on the stock with a $206 price target. In pre-market trading, Sage Therapeutics shares are up $34.49, or 35%, to $132.
12/27/18
PIPR
12/27/18
NO CHANGE
Target $206
PIPR
Overweight
Sage's 217 PPD data to be 'important' inflection point in Q1, says Piper Jaffray
Piper Jaffray analyst Danielle Brill told investors in a research note that data from Sage Therapeutics' ongoing trial with 217 in postpartum depression will be an important inflection point for the company in 1Q19 and says she remains bullish ahead of the data. The analyst, who has an Overweight rating and $206 price target on Sage shares, says she is "comfortable" that 217's MOA and PK profiles are very closely related to brex and it should achieve similar anti-depressant effects in the ongoing pivotal PPD trial.

TODAY'S FREE FLY STORIES

AZZ

AZZ Inc.

$45.54

-1.08 (-2.32%)

06:21
05/20/19
05/20
06:21
05/20/19
06:21
Hot Stocks
AZZ Inc. appoints Grant Thornton as accounting, audit firm »

AZZ Inc. announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

XOG

Extraction Oil & Gas

$3.97

-0.2 (-4.80%)

06:20
05/20/19
05/20
06:20
05/20/19
06:20
Initiation
Extraction Oil & Gas initiated  »

Extraction Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BP

BP

$42.34

0.02 (0.05%)

06:18
05/20/19
05/20
06:18
05/20/19
06:18
Periodicals
BP ramped up Arctic drilling campaign after Trump's election, Guardian reports »

BP ramped up its campaign…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

DAL

Delta Air Lines

06:18
05/20/19
05/20
06:18
05/20/19
06:18
Downgrade
Delta Air Lines rating change  »

Delta Air Lines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 12

    Jun

  • 20

    Jun

SRCI

SRC Energy

$5.46

-0.06 (-1.09%)

06:18
05/20/19
05/20
06:18
05/20/19
06:18
Initiation
SRC Energy initiated  »

SRC Energy resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDCE

PDC Energy

$36.67

-0.55 (-1.48%)

06:16
05/20/19
05/20
06:16
05/20/19
06:16
Initiation
PDC Energy initiated  »

PDC Energy resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

UAL

United Continental

$81.52

-1.07 (-1.30%)

06:15
05/20/19
05/20
06:15
05/20/19
06:15
Upgrade
United Continental rating change  »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 29

    May

KEYS

Keysight Technologies

$81.88

-3.33 (-3.91%)

06:14
05/20/19
05/20
06:14
05/20/19
06:14
Downgrade
Keysight Technologies rating change  »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

CRZO

Carrizo Oil & Gas

$12.92

-0.07 (-0.54%)

06:13
05/20/19
05/20
06:13
05/20/19
06:13
Initiation
Carrizo Oil & Gas initiated  »

Carrizo Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$35.33

0.27 (0.77%)

, SATS

EchoStar

$40.42

-0.21 (-0.52%)

06:13
05/20/19
05/20
06:13
05/20/19
06:13
Hot Stocks
Dish to acquire EchoStar BSS Business in all-stock transaction valued at $800M »

Dish (DISH) and EchoStar…

DISH

Dish

$35.33

0.27 (0.77%)

SATS

EchoStar

$40.42

-0.21 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$52.34

0.19 (0.36%)

06:11
05/20/19
05/20
06:11
05/20/19
06:11
Periodicals
Capital Re buys Juul shares valuing company over $38B, NY Post reports »

Capital Re has purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AACAY

AAC Technologies

$0.00

(0.00%)

06:10
05/20/19
05/20
06:10
05/20/19
06:10
Upgrade
AAC Technologies rating change  »

AAC Technologies upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTES

NetEase

$266.54

-12.69 (-4.54%)

, DIS

Disney

$135.04

-0.46 (-0.34%)

06:10
05/20/19
05/20
06:10
05/20/19
06:10
Hot Stocks
NetEase enters strategic partnership with Marvel Entertainment »

NetEase (NTES) and Marvel…

NTES

NetEase

$266.54

-12.69 (-4.54%)

DIS

Disney

$135.04

-0.46 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    Jun

LH

LabCorp

$164.45

-0.5 (-0.30%)

, DGX

Quest Diagnostics

$97.24

0.76 (0.79%)

06:10
05/20/19
05/20
06:10
05/20/19
06:10
Recommendations
LabCorp, Quest Diagnostics, UnitedHealth analyst commentary  »

LabCorp price target…

LH

LabCorp

$164.45

-0.5 (-0.30%)

DGX

Quest Diagnostics

$97.24

0.76 (0.79%)

UNH

UnitedHealth

$241.42

4.15 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 23

    Jun

LPX

Louisiana-Pacific

$23.88

-0.29 (-1.20%)

06:09
05/20/19
05/20
06:09
05/20/19
06:09
Upgrade
Louisiana-Pacific rating change  »

Louisiana-Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RDY

Dr. Reddy's

$39.31

-0.86 (-2.14%)

06:09
05/20/19
05/20
06:09
05/20/19
06:09
Downgrade
Dr. Reddy's rating change  »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JACK

Jack in the Box

$82.22

3.27 (4.14%)

06:09
05/20/19
05/20
06:09
05/20/19
06:09
Upgrade
Jack in the Box rating change  »

Jack in the Box upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 08

    Aug

TGT

Target

$70.88

-0.06 (-0.08%)

06:09
05/20/19
05/20
06:09
05/20/19
06:09
Upgrade
Target rating change  »

Target upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 12

    Jun

MIK

Michaels

$10.46

-0.145 (-1.37%)

06:08
05/20/19
05/20
06:08
05/20/19
06:08
Downgrade
Michaels rating change  »

Michaels downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

SATS

EchoStar

$40.42

-0.21 (-0.52%)

, DISH

Dish

$35.33

0.27 (0.77%)

06:08
05/20/19
05/20
06:08
05/20/19
06:08
Hot Stocks
EchoStar announces agreement to transfer BSS Business to Dish »

EchoStar (SATS) announced…

SATS

EchoStar

$40.42

-0.21 (-0.52%)

DISH

Dish

$35.33

0.27 (0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$76.65

-0.18 (-0.23%)

06:08
05/20/19
05/20
06:08
05/20/19
06:08
Downgrade
Prologis rating change  »

Prologis downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 04

    Jun

LSI

Life Storage

$95.51

-0.3 (-0.31%)

06:08
05/20/19
05/20
06:08
05/20/19
06:08
Upgrade
Life Storage rating change  »

Life Storage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 04

    Jun

EOG

EOG Resources

06:07
05/20/19
05/20
06:07
05/20/19
06:07
Upgrade
EOG Resources rating change  »

EOG Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

EQT

EQT Corporation

$20.80

-0.2 (-0.95%)

06:07
05/20/19
05/20
06:07
05/20/19
06:07
Upgrade
EQT Corporation rating change  »

EQT Corporation upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEC

Cimarex Energy

$68.58

-0.69 (-1.00%)

06:06
05/20/19
05/20
06:06
05/20/19
06:06
Upgrade
Cimarex Energy rating change  »

Cimarex Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.